We are a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation.

SEC Filings

Press Releases

Scaled-up, proprietary GMP manufacturing process to be utilized in 2 clinical trials:2022 planned monotherapy IMX-110 Clinical Trial in soft tissue sarcoma (“STS”)2022 planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab Clinical Trial in advanced solid tumors A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/49d68ad5-624b-46b9-8f15-cc07b6717d92 LOS ANGELES, […]
One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugsIMX-110 is in […]
LOS ANGELES, May 09, 2022 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, today announced that its board of directors has authorized a share repurchase program to acquire up to $1 […]

Email Updates

In The News

Published: Jan. 19, 2022 at 8:09 a.m. ET By Chris Wack Immix Biopharma Inc. said it saw positive interim clinical trial safety data demonstrating 100% completion of IMX-110 planned treatment cycles in its ongoing Phase 1b/2a clinical trial. The company said that historically, 43% to 67% […]
Jan. 19, 2022 9:13 AM ET Immix Biopharma, Inc. (IMMX) By: Dulan Lokuwithana, SA News Editor – Immix Biopharma (NASDAQ:IMMX) is trading ~3.6% higher after announcing 100% completion of planned treatment cycles in an ongoing Phase 1b/2a clinical trial for IMX-110, its candidate for soft tissue […]
January 4, 2022Kristi Rosa The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma. The FDA has granted a rare pediatric disease designation (RPDD) to IMX-110 for the treatment of rhabdomyosarcoma, according to an announcement from Immix Biopharma, Inc., the […]
Pre-market Movers: IMMX… ContributorRTTNews.com RTTNews PublishedJan 4, 2022 7:33AM EST (RTTNews) – The following are some of the stocks making big moves in Tuesday’s pre-market trading (as of 07.20 A.M. ET). In the Green Immix Biopharma, Inc. (IMMX) is up over 18% at $6.85… Original Article […]
EXCLUSIVE: Immix CEO On ‘Benzinga Live’ Adam Eckert , Benzinga Staff Writer January 03, 2022 3:05pm Immix Biopharma Inc IMMX +62.36% stock is soaring Monday after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation for IMX-110 for the treatment of rhabdomyosarcoma, a life-threatening […]
Reuters January 3, 2022 9:40 AM PST Reuters** Immix Biopharma Inc (IMMX.O): up 109.3% BUZZ-Immix Biopharma jumps on rare-disease tag for pediatric cancer drug Original Article Link
Jan. 03, 2022 8:46 AM ET Immix Biopharma, Inc. (IMMX) By: Dulan Lokuwithana, SA News Editor – Immix Biopharma (NASDAQ:IMMX) has jumped ~56.7% in the pre-market on above average volume after the company announced that the FDA granted the Rare Pediatric Disease (RPD) designation for IMX-110, […]
Published: Jan. 3, 2022 at 12:03 p.m. ETBy Colin Kellaher Shares of Immix Biopharma Inc. more than doubled on Monday after the biopharmaceutical company’s lead product candidate received rare-pediatric-disease designation from the U.S. Food and Drug Administration. The Los Angeles company said the designation covers IMX-110 […]
Seeking Alpha / Avisol Capital Partners Sep. 28, 2021 2:12 PM ET Immix Biopharma, Inc. (IMMX) Summary Immix Biopharma is developing Tissue-Specific Therapeutics in oncology and inflammation with a Tumor Micro-Environment Normalization technology.The Company’s lead candidate has shown promising results in ongoing Phase 1b/2a trials.The Company […]

Events

Currently, there are no future events scheduled. Please check back soon.